Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial

Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis

(2016) E. G. Meissner et al.   JOURNAL OF VIRAL HEPATITIS

Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014

(2015) Natalie J. Torok et al.   HEPATOLOGY

Fibrosis — A Common Pathway to Organ Injury and Failure

(2015) Don C. Rockey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study

(2014) I. Vodkin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma

(2014) Carmen Chak-Lui Wong et al.   HEPATOLOGY

Transforming growth factor β3 attenuates the development of radiation-induced pulmonary fibrosis in mice by decreasing fibrocyte recruitment and regulating IFN-γ/IL-4 balance

(2014) Long Xu et al.   IMMUNOLOGY LETTERS

Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome

(2014) Eric G. Meissner et al.   JOURNAL OF CLINICAL INVESTIGATION

Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy

(2014) P. Labarga et al.   JOURNAL OF VIRAL HEPATITIS

Hepatitis C Virus-Induced Changes in MicroRNA 107 (miRNA-107) and miRNA-449a Modulate CCL2 by Targeting the Interleukin-6 Receptor Complex in Hepatitis

(2014) N. J. Sarma et al.   JOURNAL OF VIROLOGY

Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets

(2013) Z. M. Younossi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression

(2013) Shubham Shrivastava et al.   HEPATOLOGY

1319 SIMTUZUMAB, AN ANTIFIBROTIC MONOCLONAL ANTIBODY AGAINST LYSYL OXIDASE-LIKE 2 (LOXL2) ENZYME, APPEARS SAFE AND WELL TOLERATED IN PATIENTS WITH LIVER DISEASE OF DIVERSE ETIOLOGY

(2013) A.H. Talal et al.   JOURNAL OF HEPATOLOGY

Therapy for Fibrotic Diseases: Nearing the Starting Line

(2013) S. L. Friedman et al.   Science Translational Medicine

Pathogenesis of Liver Fibrosis

(2011) Virginia Hernandez-Gea et al.   Annual Review of Pathology-Mechanisms of Disease

Effects of p-CREB-1 on transforming growth factor-β3 auto-regulation in hepatic stellate cells

(2011) Liang Deng et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

rAAV2-TGF-β3 Decreases Collagen Synthesis and Deposition in the Liver of Experimental Hepatic Fibrosis Rat

(2010) Yi Zhang et al.   DIGESTIVE DISEASES AND SCIENCES

Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment

(2010) Vivian Barry-Hamilton et al.   NATURE MEDICINE

Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection

(2009) John McHutchison et al.   GASTROENTEROLOGY

Magnetic resonance elastography in the liver at 3 Tesla using a second harmonic approach

(2009) D.A. Herzka et al.   MAGNETIC RESONANCE IN MEDICINE

Magnetic Resonance Elastography for the Noninvasive Staging of Liver Fibrosis

(2008) Laurent Huwart et al.   GASTROENTEROLOGY